Patanjali finds coronavirus cure in Ayurveda; claims 100% favourable result

We are not talking about an immunity booster. We are talking about a cure," said Acharya Balkrishna, managing director of Patanjali

Balkrishna
File photo of Acharya Balkrishna
Agencies New Delhi
2 min read Last Updated : Jun 15 2020 | 7:34 AM IST
Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali has claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days.

"We appointed a team of scientists after Covid-19 outbreak. Firstly, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results," Balkrishna said.

"We are not talking about an immunity booster.  We are talking about a cure," said Acharya Balkrishna, managing director of Patanjali.
The clinical trials were conducted in Indore and in Jaipur after Patanjali secured permission last week.

"After taking our medicine, Covid patients recovered in 5-14 days and then tested negative. So, we can say the cure for Covid is possible through Ayurveda. We are performing controlled clinical trials only. In the next few days, evidence and data will be released by us," he added.

The Patanjali CEO further said that people should practice Yoga, and keep oneself healthy through proper diet to boost the immune system..

Coronavirus treatment update

So far, there is no vaccine or cure for the novel coronavirus. Patanjali's decision to diversify into the hunt for a cure for the deadly pandemic is unusual for because the rush to develop treatments for Covid-19 has so far been led by large pharmaceutical companies such as Gilead Sciences, Pfizer, Johnson & Johnson, Moderna, Inovio Pharmaceutcials and GlaxoSmithKline, among others.



One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownDharavi SlumAtmanirbhar Bharat MissionCorona RemediesPatanjaliRamdev

Next Story